The true cost of laboratory investment: what most financial models miss

The Hidden Cost Problem

Laboratory investment decisions are typically evaluated on capital expenditure and direct operating costs. This approach consistently underestimates the true cost of ownership by 30-50%, because it fails to account for the indirect, escalating, and systemic costs that accumulate over the asset lifecycle.

Consumable drift, maintenance escalation, staffing implications, facility adaptation costs, and the opportunity cost of suboptimal procurement decisions are rarely modeled with the rigor they deserve. The result is investment decisions that look sound at approval but underperform over the 7-10 year ownership horizon.

What Gets Missed

Consumable cost escalation: reagent and consumable costs typically increase 3-7% annually, compounding significantly over a 7-10 year instrument lifecycle. Most financial models use static pricing. Maintenance trajectory: service contracts escalate predictably after warranty periods, but the escalation curve is rarely modeled accurately at the point of procurement.

Staffing implications: new instrumentation changes workflow requirements, skill mix needs, and training demands. These costs are real but rarely included in the investment case. Facility adaptation: laboratory equipment has specific environmental requirements that may require facility modifications not captured in the equipment budget.

Opportunity cost: suboptimal procurement decisions lock organizations into vendor relationships and technology platforms that constrain future flexibility. The cost of switching or upgrading is the hidden tax on poor initial decisions.

The eValuate Approach

eValuate is LTS Global's proprietary decision-support tool designed to provide laboratory leaders with accurate, comprehensive total cost of ownership modeling. It captures the full spectrum of direct and indirect costs across the complete asset lifecycle.

By modeling scenarios across multiple vendors, configurations, and implementation timelines, eValuate enables decision-makers to compare options on a genuinely like-for-like basis, accounting for the costs that traditional procurement processes overlook.

The result is investment decisions that are grounded in reality rather than optimistic assumptions, protecting organizations from the cost overruns and performance shortfalls that characterize most laboratory procurement.